circle with rainbow colors

Perspectives

2021 Life sciences regulatory outlook

Navigating key trends in life sciences regulatory compliance

Gain industry insight into key life sciences regulations and get updates on what companies should be tracking and addressing in 2021.

On August 6, 2021, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced[1] that it updated its Code on Interactions with Health Care Professionals[2] (“PhRMA Code”). The PhRMA Code was previously updated in 2019 and is a voluntary code of ethics applicable to pharmaceutical company interactions with US health care professionals (HCPs). The PhRMA code will take effect on January 1, 2022. The most significant PhRMA updates relate to speaker programs and speaker training meetings.

Read our alert for a summary of the new insertions into the PhRMA code and other critical changes and to explore Deloitte’s insights on what it means for life sciences organizations.


1 PhRMA, “Statement on Revisions to the PhRMA Code on Interactions with Health Care Professionals,” Speeches & Communication, August 6, 2021.
2 PhRMA, “Code on Interactions with Health Care Professionals,” effective January 1, 2022.

Life sciences regulations in 2021: What’s changed?

Over the past several years, life sciences companies have faced mounting pressure from many directions, including increasing regulatory requirements, nonstop technological advances, and intense pricing pressure. And the unprecedented events of the past year only provided more reason to modernize compliance and elevate the value and partnerships within your companies and external stakeholders.

To continue thriving and leading, life sciences companies should meet the industry’s new challenges head-on. Now is the ideal time for the compliance function to evolve its focus from hindsight to foresight.

The overarching theme for this year’s regulatory outlook is for life sciences companies to take a closer look at their compliance activities as an integral part of their overall business strategy.

More life sciences trends and insights

  • Read Deloitte's 2021 global life sciences outlook for insights on how life sciences companies continue to respond to the impacts of the pandemic and in what areas they can build resilience going forward

Get in touch





Paul Silver
Principal | Deloitte & Touche LLP
psilver@deloitte.com
+1 404 631 2157




Jack Tanselle
Managing director | Deloitte & Touche LLP
jtanselle@deloitte.com
+1 317 656 2452




Marcy Imada
Managing director | Deloitte & Touche LLP
mimada@deloitte.com
+1 213 553 1642

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.